Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Research Reviews
  4. Volume 17, Issue 1
  5. Article
Volume 17, Issue 1
  • ISSN: 2589-9775
  • E-ISSN: 2589-9783

Abstract

Chronic pain is a byproduct of many diseases and conditions. Along with long-term opioid medication use in chronic pain management, misuse of this vital medication has been a topic of much debate over the last two decades. Abuse-deterrent formulations play a critical role in comprehensive opioid risk management strategies, limiting the attractiveness and drug-liking qualities of an opioid drug by limiting their bioavailability, making abuse of the tampered opioid medication less appealing or rewarding, or impeding the extraction of the opioid drug and thus impeding the administration of the opioid formulation alternative routes. The present article covers various regulatory actions, expectations in abuse-deterrent formulation approval, and emerging opioid abuse-deterrent formulation strategies, such as incorporating physical barriers, chemical barriers, aversion agents, pH modulating release properties, novel delivery systems, agonist/antagonist combinations, and prodrugs, as potential approaches to encountering the crisis of the opioid abuse epidemic. Looking at the severity of the opioid crisis across the globe now is the right time for various regulatory agencies to come under one roof to save society from the opioid epidemic, define the policy on how and when to prescribe opioid formulations to patients, perform abuse risk assessments, and make more efforts to approve only abuse-deterrent opioid medication.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdrr/10.2174/0125899775274502231210060016
2023-12-19
2025-05-07

  • From This Site

    /content/journals/cdrr/10.2174/0125899775274502231210060016
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ErinK AhmedE SaadM Legislative initiatives and review of abuse-deterrent opioid formulations.US Pharm201338102126
     [Google Scholar]
  2. ManchikantiL. FellowsB. AilinaniH. PampatiV. Therapeutic use, abuse, and nonmedical use of opioids: A ten-year perspective.Pain Physician201051340143510.36076/ppj.2010/13/40120859312
     [Google Scholar]
  3. ToblinR.L. PaulozziL.J. LoganJ.E. HallA.J. KaplanJ.A. Mental illness and psychotropic drug use among prescription drug overdose deaths: A medical examiner chart review.J. Clin. Psychiatry201071449149610.4088/JCP.09m05567blu20409446
     [Google Scholar]
  4. Joint meeting of the anesthetic and life support drugs advisory committee and the drug safety and risk management advisory committee. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics.2010Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM217510.pdf (Accessed on: July 22-23, 2010).
  5. PaulozziL.J. BudnitzD.S. XiY. Increasing deaths from opioid analgesics in the United States.Pharmacoepidemiol. Drug Saf.200615961862710.1002/pds.127616862602
     [Google Scholar]
  6. KuehnB.M. Opioid prescriptions soar: Increase in legitimate use as well as abuse.JAMA2007297324925117227967
     [Google Scholar]
  7. N. I. Drug Abuse. Misuse of Prescription Drugs. Retrieved from National Institute of Drug Abuse.2016https://www.drugabuse.gov/publications/research-reports/ misuse-prescription-drugs/how-can-prescription-drug-misuse-be-prevented
  8. United Nations Office on Drugs and CrimeWorld Drug Report.2015Available from: www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf
  9. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: Results from the 2014 national survey on drug use and health.HHS Publication No. SMA 15-4927, NSDUH Series H-502015Available from: www.samhsa.gov/data/sites/default/files/NSDUH-FRR1–2014/NSDUH-FRR1–2014.htm
    [Google Scholar]
  10. KuehnB.M. Prescription drug abuse rises globally.JAMA200729712130310.1001/jama.297.12.130617392232
     [Google Scholar]
  11. CasatiA. SedefovR. Pfeiffer-GerschelT. Misuse of medicines in the European Union: A systematic review of the literature.Eur. Addict. Res.201218522824510.1159/00033702822572594
     [Google Scholar]
  12. FischerB. IalomiteanuA. BoakA. AdlafE. RehmJ. MannR.E. Prevalence and key covariates of non‐medical prescription opioid use among the general secondary student and adult populations in O ntario, C anada.Drug Alcohol Rev.201332327628710.1111/dar.1202523305232
     [Google Scholar]
  13. BlanchB. PearsonS.A. HaberP.S. An overview of the patterns of prescription opioid use, costs and related harms in A ustralia.Br. J. Clin. Pharmacol.20147851159116610.1111/bcp.1244624962372
     [Google Scholar]
  14. van AmsterdamJ. van den BrinkW. The misuse of prescription opioids: A threat for Europe?Curr. Drug Abuse Rev.20158131410.2174/18744737080115061118421826084418
     [Google Scholar]
  15. Australian Institute of Health and Welfare. National Drug Strategy Household Survey detailed report.2014Available from: www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129549848
  16. TominagaM. KawakamiN. OnoY. NakaneY. NakamuraY. TachimoriH. IwataN. UdaH. NakaneH. WatanabeM. NaganumaY. FurukawaT.A. HataY. KobayashiM. MiyakeY. TakeshimaT. KikkawaT. Prevalence and correlates of illicit and non-medical use of psychotropic drugs in Japan.Soc. Psychiatry Psychiatr. Epidemiol.200944977778310.1007/s00127‑009‑0499‑119190833
     [Google Scholar]
  17. BirnbaumH.G. WhiteA.G. SchillerM. WaldmanT. ClevelandJ.M. RolandC.L. Societal costs of prescription opioid abuse, dependence, and misuse in the United States.Pain Med.201112465766710.1111/j.1526‑4637.2011.01075.x21392250
     [Google Scholar]
  18. KatzN.P. BirnbaumH. BrennanM.J. FreedmanJ.D. GilmoreG.P. JayD. KennaG.A. MadrasB.K. McElhaneyL. WeissR.D. WhiteA.G. Prescription opioid abuse: Challenges and opportunities for payers.Am. J. Manag. Care201319429530223725361
     [Google Scholar]
  19. FarréM. CamíJ. Pharmacokinetic considerations in abuse liability evaluation.Addiction199186121601160610.1111/j.1360‑0443.1991.tb01754.x1786493
     [Google Scholar]
  20. JonesJ.D. MogaliS. ComerS.D. Polydrug abuse: A review of opioid and benzodiazepine combination use.Drug Alcohol Depend.20121251-281810.1016/j.drugalcdep.2012.07.00422857878
     [Google Scholar]
  21. GudinJ.A. MogaliS. JonesJ.D. ComerS.D. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use.Postgrad. Med.2013125411513010.3810/pgm.2013.07.268423933900
     [Google Scholar]
  22. KatzN. DartR.C. BaileyE. TrudeauJ. OsgoodE. PaillardF. Tampering with prescription opioids: Nature and extent of the problem, health consequences, and solutions.Am. J. Drug Alcohol Abuse201137420521710.3109/00952990.2011.56962321517709
     [Google Scholar]
  23. KirshK. PeppinJ. ColemanJ. Characterization of prescription opioid abuse in the United States: Focus on route of administration.J. Pain Palliat. Care Pharmacother.201226434836110.3109/15360288.2012.73490523675595
     [Google Scholar]
  24. GasiorM. BondM. MalamutR. Routes of abuse of prescription opioid analgesics: A review and assessment of the potential impact of abuse-deterrent formulations.Postgrad. Med.20161281859610.1080/00325481.2016.112064226566680
     [Google Scholar]
  25. ButlerS.F. BlackR.A. CassidyT.A. DaileyT.M. BudmanS.H. Abuse risks and routes of administration of different prescription opioid compounds and formulations.Harm Reduct. J.2011812910.1186/1477‑7517‑8‑2922011626
     [Google Scholar]
  26. Questions and answers: FDA approves a Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting opioid analgesics.2012Available from: www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm309742.htm
  27. Extended-release (ER) and long-acting (LA) opioid analgesics Risk Evaluation and Mitigation Strategy (REMS).2013Available from: www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf
  28. FDA announces safety labeling changes and post market study requirements for extended-release and long-acting opioid analgesics. FDA news release.2013Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367726.htm (Accessed on: September 10, 2013).
  29. KatzN.P. AdamsE.H. ChilcoatH. ColucciR.D. ComerS.D. GoliberP. GrudzinskasC. JasinskiD. LandeS.D. PassikS.D. SchnollS.H. SellersE. TraversD. WeissR. Challenges in the development of prescription opioid abuse-deterrent formulations.Clin. J. Pain200723864866010.1097/AJP.0b013e318125c5e817885342
     [Google Scholar]
  30. SimonK. WorthyS.L. BarnesM.C. TarbellB. Abuse-deterrent formulations: Transitioning the pharmaceutical market to improve public health and safety.Ther. Adv. Drug Saf.201562677910.1177/204209861556972625922655
     [Google Scholar]
  31. JayendrakumarP. RakeshP. Self-regulated anti-overdose crush and extraction-resistant drug delivery system to combat opioid overdose crisis.AAPS PharmSciTech202223726510.1208/s12249‑022‑02423‑536163600
     [Google Scholar]
  32. PatelJ.D. PatelS.D. Tamper resistant pharmaceutical composition.US Patent Application number: US20180064817A12019
  33. PatelJ.D. PatelK.J. PatelS.D. Tamper resistant pharmaceutical composition.Patent US20180064817A1, 2018.
     [Google Scholar]
  34. PatelJ.D. Pharmaceutical abuse deterrent composition constructed in more than one strengths.US20210046014A12021
  35. BenivalD. RanaD. SalaveS. Emerging trends in abuse-deterrent formulations: Technological insights and regulatory considerations.Curr. Drug Deliv.202219884685910.2174/156720181866621120810103534879799
     [Google Scholar]
  36. SchaefferT. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.J. Med. Toxicol.20128440040710.1007/s13181‑012‑0270‑y23073726
     [Google Scholar]
  37. LitmanR.S. PagánO.H. CiceroT.J. Abuse-deterrentO.F. Abuse-deterrent opioid formulations.Anesthesiology201812851015102610.1097/ALN.000000000000203129252508
     [Google Scholar]
  38. HaleM.E. MoeD. BondM. GasiorM. MalamutR. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.Pain Manag.20166549750810.2217/pmt‑2015‑0005
     [Google Scholar]
  39. WuK.M. FarrellyJ.G. Regulatory perspectives of Type II prodrug development and time-dependent toxicity management: Nonclinical Pharm/Tox analysis and the role of comparative toxicology.Toxicology20072361-21610.1016/j.tox.2007.04.00517507137
     [Google Scholar]
  40. WebsterL.R. BathB. MedveR.A. Opioid formulations in development designed to curtail abuse: Who is the target?Expert Opin. Investig. Drugs200918325526310.1517/1354378090275162219243277
     [Google Scholar]
  41. MastropietroD.J. OmidianH. Current approaches in tamper-resistant and abuse-deterrent formulations.Drug Dev. Ind. Pharm.201222537282
     [Google Scholar]
  42. MiyazakiT. ChoiI.Y. RubasW. AnandN.K. AliC. EvansJ. GursahaniH. HennessyM. KimG. McWeeneyD. PfeifferJ. QuachP. GauvinD. RileyT.A. RiggsJ.A. GogasK. ZalevskyJ. DobersteinS.K. NKTR-181: A novel Mu-Opioid analgesic with inherently low abuse potential.J. Pharmacol. Exp. Ther.2017363110411310.1124/jpet.117.24303028778859
     [Google Scholar]
  43. GudinJ. FudinJ. Analgesics of the future: Low abuse liability opioids-wish list or emerging treatment?Pract. Pain Manag.2022221
     [Google Scholar]
  44. U.S. Food and Drug Administration: Abuse-deterrent opioids—evaluation and labeling. Guidance for industry.2015Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdf
  45. BeckerW.C. FiellinD.A. Abuse-deterrent opioid formulations-putting the potential benefits into perspective.N. Engl. J. Med.2017376222103210510.1056/NEJMp170155328564568
     [Google Scholar]
  46. CiceroT.J. EllisM.S. SurrattH.L. Effect of abuse-deterrent formulation of OxyContin.N. Engl. J. Med.2012367218718910.1056/NEJMc120414122784140
     [Google Scholar]
  47. KatzN. Abuse-deterrent opioid formulations: Are they a pipe dream?Curr. Rheumatol. Rep.2008101111810.1007/s11926‑008‑0003‑z18457606
     [Google Scholar]
  48. KarstK.R. STOPP act would establish new requirements for tamper-resistant drugs.2012Available from: http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2012/07/stopp-act-would-establish-new-requirements-for-tamper-resistant-drugs.html
/content/journals/cdrr/10.2174/0125899775274502231210060016
Loading
Advancement in Opioid Abuse-deterrent Formulation Technologies and Regulatory Expectation
Current Drug Research Reviews 17, 90 (2025); https://doi.org/10.2174/0125899775274502231210060016
/content/journals/cdrr/10.2174/0125899775274502231210060016
/content/journals/cdrr/10.2174/0125899775274502231210060016
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): abuse-deterrent technology; chronic pain; extraction; Opioid; overdose; regulatory

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test